A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE
THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR
EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR
ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC
CARDIOVASCULAR EVENT ¿ MOVE-LP(A)
- Registry ID
- J2O-MC-EKBG
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2025-08-29
- Last update
- 2025-07-22
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY
TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON THE INCIDENCE OF MAJOR ADVERSE
CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE (ATTAIN-OUTCOMES)
- ZENITH: A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
TO EVALUATE THE EFFICACY AND SAFETY OF ZILEBESIRAN IN ADDITION TO STANDARD OF CARE
IN REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULT PATIENTS WITH
HYPERTENSION NOT ADEQUATELY CONTROLLED AND WITH EITHER ESTABLISHED
CARDIOVASCULAR DISEASE OR HIGH RISK FOR CARDIOVASCULAR DISEASE
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE IMPACT OF MARIDEBART CAFRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN
PARTICIPANTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OVERWEIGHT OR
OBESITY (MARITIME-CV)
- A PHASE III DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP SUPERIORITY TRIAL TO EVALUATE EFFICACY AND SAFETY OF THE COMBINED USE OF ORAL VICADROSTAT (BI 690517) AND EMPAGLIFLOZIN COMPARED WITH PLACEBO AND EMPAGLIFLOZIN IN PARTICIPANTS WITH TYPE 2 DIABETES, HYPERTENSION AND ESTABLISHED CARDIOVASCULAR DISEASE. (EASI¿-PROTKT)
- A SINGLE ARM, MULTICENTER, OPEN-LABEL EXTENSION (OLE) TRIAL TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF PELACARSEN (TQJ230) IN PARTICIPANTS WHO COMPLETED THE PARENT LP(A)HORIZON TRIAL
- A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFECT OF OLPASIRAN ON CORONARY ARTERY PLAQUE BURDEN ASSESSED BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY IN PARTICIPANTS WITH STABLE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND ELEVATED LIPOPROTEIN(A)
View on source registry